Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03982004
Recruitment Status : Not yet recruiting
First Posted : June 11, 2019
Last Update Posted : June 13, 2019
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
The purpose of this research study is to look at the safety and side effects of combining the drug pembrolizumab with imiquimod, GM-CSF, and cryotherapy to treat breast cancer that includes skin lesions.

Condition or disease Intervention/treatment Phase
Metastatic Breast Cancer Device: Epicutaneous cryoimmunotherapy Drug: Topical imiquimod Drug: Pembrolizumab Other: Dermatologic Quality of Life Index Other: Functional Assessment of Cancer Therapy Drug: Intra-lesional GM-CSF Device: Cry-AC Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Estimated Study Start Date : August 31, 2019
Estimated Primary Completion Date : November 30, 2021
Estimated Study Completion Date : August 31, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Epicutaneous cryoimmunotherapy+imiquimod+pembrolizumab+GM-CSF
  • Epicutaneous cryoimmunotherapy treatments (6 total) during weeks 1-14 (every 2 weeks for 5 weeks, then every 3 weeks until week 14)
  • Topical imiquimod will be applied 5 days per week (Weeks 1-12)
  • Pembrolizumab will be given every 3 weeks starting at Week 5 until disease progression or unacceptable toxicity.
  • Intra-lesional GM-CSF 250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses
Device: Epicutaneous cryoimmunotherapy
Epicutaneous cryoimmunotherapy (EC) treatment includes liquid nitrogen cryotherapy applied for 10 seconds x 2 freeze-thaw cycles. Four treatment areas will be chosen at each treatment.

Drug: Topical imiquimod
Patients will apply the cream directly over the treatment areas and can use up to one packet per day (covers approximately 5 cm x 5 cm).

Drug: Pembrolizumab
Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks
Other Name: Keytruda

Other: Dermatologic Quality of Life Index
  • 10 questions about how much skin problems has affected the participant's life over the past week
  • The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3
  • The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired.
Other Name: DLQI

Other: Functional Assessment of Cancer Therapy
  • 5 subscales (physical well-being, social/family well-being, emotional well-being, functional well-being, and additional concerns)
  • Answers ranging from 0=Not at all to 4 = very much
  • Each item is rated on a 5-point Likert scale.
  • The higher the score on the social/family well-being and functional well-being indicate higher quality of life
  • The lower the score on physical well-being, emotional well-being, and additional concerns indicate higher quality of life
Other Name: FACT-B

Drug: Intra-lesional GM-CSF
250 mcg every 2 weeks x 3 doses then every 3 weeks for 3 doses

Device: Cry-AC
-Device used to give the cryoimmunotherapy




Primary Outcome Measures :
  1. Safety and tolerability as measured by rate of treatment emergent grade 3 or higher toxicities [ Time Frame: From beginning of treatment through 90 days following completion of treatment or 30 days following completion of treatment if the participant initiates new therapy (whichever is earlier) ]
    -NCI Common terminology criteria for adverse events (CTCAE v5.0) will be used to grade toxicities


Secondary Outcome Measures :
  1. Objective response rate (ORR) as measured by RECIST 1.1 [ Time Frame: Baseline and 18 weeks ]
    • For patients who present with discrete measurable lesions
    • ORR = number of patients who achieve CR or PR divided by the total number response-evaluable patients
    • Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
    • Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

  2. Progression-free survival (PFS) [ Time Frame: 2 years ]
    • Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).
    • PFS is defined from date on treatment to the earliest date of progression, death, or last follow-up and progression or death are events of interest for PFS.

  3. Change from baseline to week 5 in the number of tumor infiltrating lymphocytes after epicutaneous cryoimmunotherapy [ Time Frame: Baseline and week 5 ]
  4. Change from week 6 to week 10 in the number of tumor infiltrating lymphocytes after epicutaenous cryoimmunotherapy plus 2 cycles of pemrolizumab [ Time Frame: Week 6 and week 10 ]
  5. Change from baseline to 18 weeks in the number of tumor cells [ Time Frame: Baseline and 18 weeks ]
  6. Change in quality of life as measured by the Dermatologic Quality of Life Index [ Time Frame: Baseline and 18 weeks ]
    • 10 questions about how much skin problems has affected the participant's life over the past week
    • The scoring of each question is as follows: very much = 3, a lot = 2, a little = 1, not at all = 0, not relevant = 0, and question #7 'prevented work or studying' = 3
    • The DLQI is calculated by summing the score of each question resulting in a max of 30 and min of 0. The higher the score, the more quality of life is impaired.

  7. Change in quality of life as measured by the Functional Assessment of Cancer Therapy (FACT) [ Time Frame: Baseline and 18 weeks ]
  8. Objective response rate as measured by measurement of 2 sentinel lesions [ Time Frame: Baseline and 18 weeks ]
    -Largest diameter in 2 dimensions

  9. Objective response rate as measured by photography-based estimates of body surface area [ Time Frame: Baseline and 18 weeks ]
  10. Objective response rate as measured by five point overall severity scale [ Time Frame: Baseline and 18 weeks ]
    -None, minimal, mild, moderate, severe

  11. Objective response rate as measured by minutes spent per week for wound care [ Time Frame: Baseline and 18 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed locally advanced unresectable or metastatic breast cancer with cutaneous metastasis with progression after one or more therapies including endocrine therapies for estrogen receptor positive breast cancer.
  • Failed at least 1 prior therapies
  • Patients can have concurrent maintenance therapy (including endocrine therapy, pertuzumab, or trastuzumab) if they have had stable or progressive cutaneous disease for 2 months prior to study entry and there is no anticipated change in maintenance therapy drug during the study period.
  • Patients that are starting a new systemic therapy must receive the new systemic therapy for at least 2 weeks before enrolling in this study.
  • Have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
  • Be willing to provide serial tumor and blood specimens (week 0, 2, 5, 10, and 18). Baseline biopsy should be performed within 2 weeks of 1st treatment.
  • At least 18 years of age on the day of signing informed consent.
  • Have a performance status of 0 or 1 on the ECOG Performance Scale. Evaluation of ECOG PS is to be performed within 7 days prior to the date of allocation.
  • Demonstrate adequate organ function (performed within 10 days of treatment initiation), defined as:

    • Absolute neutrophil count (ANC) ≥1,500 /mcL
    • Platelets ≥100,000 / mcL
    • Hemoglobin ≥9.0 g/dL or ≥5.6 mmol/L without erythropoietin dependency and without packed red blood cell transfusion within the last 2 weeks
    • Creatinine ≤1.5 X upper limit of normal (ULN) OR
    • Measured or calculateda creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥30 mL/min for subject with creatinine levels > 1.5 X institutional ULN
    • Total bilirubin ≤ 1.5 X ULN OR
    • Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
    • AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN (≤ 5 X ULN for subjects with liver metastases)
    • International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
    • Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    1. Not a woman of childbearing potential (WOCBP) OR
    2. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 12 days after the last dose of study treatment.
  • A male participant must agree to use contraception during the treatment period and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this period.
  • Ability to understand and willingness to sign an IRB approved written informed consent document.

Exclusion Criteria:

  • Has large, ulcerated, bulky tumors (defined as total volume greater than 4 x 4 x 4 cm^3 with > 50% ulceration).
  • Has life expectancy of < 6 months.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks of the first dose of treatment. Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been 4 weeks after the last dose of the previous investigational agent.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  • Has a known history of active TB (Bacillus Tuberculosis)
  • Has severe hypersensitivity (≥ grade 3) to pembrolizumab or any of its excipients.
  • Patients that have received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to study Day 1. or who.

    • Note: Participants must have recovered from all AEs due to a previous therapies to ≤ grade 1 or baseline. Subjects with ≤ Grade 2 neuropathy may be eligible.
    • Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
  • Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease.
  • Has a known additional malignancy that is progressing or requires active treatment within the past 3 years. Note: participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer) that have undergone potentially curative therapy are not excluded.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable i.e. without evidence of progression by imaging for at least four weeks prior by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
  • Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxin, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
  • Has an active infection requiring systemic therapy.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment. A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137).
  • Has a known history of Human Immunodeficiency Virus (HIV).
  • Has known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  • Has received a live vaccine within 30 days of planned start of study therapy. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03982004


Contacts
Layout table for location contacts
Contact: Leonel Hernandez-Aya, M.D. 314-747-5165 lhernandezaya@wustl.edu

Locations
Layout table for location information
United States, Kentucky
University of Louisville Not yet recruiting
Louisville, Kentucky, United States, 40292
Contact: Jae Jung, M.D., Ph.D.    502-629-4440    jae.jung@nortonhealthcare.org   
Principal Investigator: Jae Jung, M.D., Ph.D.         
United States, Missouri
Washington University School of Medicine Not yet recruiting
Saint Louis, Missouri, United States, 63110
Contact: Leonel Hernandez-Aya, M.D.    314-747-5165    lhernandezaya@wustl.edu   
Principal Investigator: Leonel Hernandez-Aya, M.D.         
Sub-Investigator: Milan Anadkat, M.D.         
Sub-Investigator: Jingqin Luo, Ph.D.         
Sponsors and Collaborators
Washington University School of Medicine
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Leonel Hernandez-Aya, M.D. Washington University School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT03982004     History of Changes
Other Study ID Numbers: 19-x150
First Posted: June 11, 2019    Key Record Dates
Last Update Posted: June 13, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Pembrolizumab
Imiquimod
Sargramostim
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic
Interferon Inducers